Granisetron reduces the incidence of nausea and vomiting after middle ear surgery.
We studied the efficacy of granisetron, a selective 5-hydroxytryptamine type-3 receptor antagonist, in preventing postoperative nausea and vomiting (PONV) after middle ear surgery. In a randomized, double-blind, placebo-controlled study, 60 ASA I patients received placebo (saline) or granisetron 40 micrograms kg-1 i.v. immediately before induction of anaesthesia (n = 30 in each group). A standard general anaesthetic technique was used. During the first 24 h after anaesthesia, the incidence of PONV in patients who had received granisetron was lower than in those who had received placebo (17% vs 63%; P < 0.05). There were no clinically important adverse effects in either group. We conclude that granisetron, given before anaesthesia, reduced the incidence of PONV after middle ear surgery.
Fujii
Y
Y
Department of Anaesthesiology, University of Tsukuba, Institute of Clinical Medicine, Ibaraki, Japan.
Toyooka
H
H
Tanaka
H
H
D000328:Adult; D000368:Aged; D000768:Anesthesia, General; D000932:Antiemetics / Q000627:therapeutic use*; D004311:Double-Blind Method; D004432:Ear, Middle / Q000601:surgery*; D005260:Female; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control*; D011229:Preanesthetic Medication; D014839:Vomiting / Q000517:prevention & control*
D000932:Antiemetics; D017829:Granisetron